Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04230226
Other study ID # 20-PHX-0001 Acute
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 21, 2020
Est. completion date September 16, 2020

Study information

Verified date November 2020
Source Pharmanex
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The acute study will evaluate pre- and post-exercise ingestion of a multi-ingredient supplement in a randomized, double-blind, placebo-controlled, crossover design. Participants will complete one enrollment visit, in which they will sign a consent form and complete a health history questionnaire. Participants will complete two interventions, with three visits each (6 visits total), in which a treatment beverage (pre/post supplement, or non-caloric placebo) will be consumed within 30 minutes prior to exercise and within 15 minutes post-exercise, in random order. Total time from enrollment to completion will be at least 14 days. Testing visits will be separated by a minimum of 7 days of rest to allow for recovery and washout, based on a half-life of ≤8 hours for all ingredients present in the supplement.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date September 16, 2020
Est. primary completion date September 16, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 50 Years
Eligibility Inclusion Criteria: - Participant is an adult between the ages of 25-50 years - Participant has a recorded BMI of 20-35 kg/m2 - Participant exercises less than 3 hours per week for at least 8 weeks preceding the study - Participant has provided written and dated informed consent to participate in the study - Participant is willing to and able to comply with the protocol - Participant is apparently healthy and no reported metabolic disorders, heart disease, arrhythmias, thyroid disease, renal, hepatic, autoimmune or neurological diseases, as determined by a health history questionnaire - Participant agrees to maintain current diet and exercise routine during the study - Participant agrees to refrain from taking any anti-inflammatory supplement 48 hours prior to exercise (acute) or medications to prevent any further nutritional or drug related protection against exercise induced muscle damage - Participant has a resting (seated for 5 minutes) blood pressure of systolic pressure between 140-90 mmHg and a diastolic pressure between 90-50 mmHg Exclusion Criteria: - Participant is currently enrolled in a separate clinical trial or weight loss program involving diet, exercise, physical activity, or the potential ingestion of an active drug or dietary supplement - Participant is using, or has consistently used one of the following dietary supplements within 12 weeks prior to enrollment: Beta-alanine, Creatine, HMB, Carnosine, Vitamin D - Participant has consistently consumed whey protein/plant protein and/or 1,000 mg of fish oil within the previous 4 weeks prior to enrollment - Participant has gained or lost = 8 lbs in the previous month - Participant has a known allergy or sensitivity to the placebo or active ingredients - Participant has used tobacco more than three days per week (on average) in the previous 6 months, or refuses to abstain from all tobacco use for the duration of the study - Participant is pregnant or planning to become pregnant - Participant has any musculoskeletal condition prohibiting them from participation

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Pre-workout plus and protein recovery plus
Study products consumed prior and after exercise
Other:
Placebo
Placebo product consumed prior and after exercise

Locations

Country Name City State
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina

Sponsors (2)

Lead Sponsor Collaborator
Pharmanex University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Performance Change from baseline on performance by measuring countermovement vertical jump height using a jump mat and associated velocity using a linear transducer. baseline, 24 hours, 48 hours
Secondary Muscle soreness Change from baseline on muscle soreness using visual analog scale (a horizontal 100 mm line where zero will represent no soreness and one-hundred will represent maximum amount of soreness. Participants will be asked to place a single vertical that represents their current soreness. The scale will be measured with a calibrated ruler with the higher numbers representing more soreness.) baseline, 24 hours, 48 hours
Secondary Creatine Kinase Change from baseline on muscle damage by measuring creatine kinase baseline, 24 hours, 48 hours
Secondary Isoprostanes Change from baseline on muscle damage by measuring isoprostanes baseline, 24 hours, 48 hours
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04203992 - Videogame for the Prevention of Doping and Supplement Abuse in Teenage Athletes N/A
Enrolling by invitation NCT04474015 - Optimizing Volunteer Comfort for Transcranial Electrical Stimulation (TES): An Assessment N/A
Completed NCT06112210 - Effect of Hyperbaric Oxygen Therapy N/A
Not yet recruiting NCT05845255 - Validation of the Mjn-SERAS Performance
Recruiting NCT06371521 - Ergogenic Effects of Sportlegs Phase 1
Completed NCT06464120 - Investigating the Post-Activation Performance Enhancement Effects on Skeletal Muscles Under Varied Loading Conditions N/A
Recruiting NCT04290819 - Effect of Creatine and Caffeine on Muscle Performance N/A
Completed NCT05295836 - Effects of Acute Glycerol Ingestion on Performance, Metabolic and Biochemical Markers in International Athletes N/A
Completed NCT04230824 - Chronic Study on Body Composition, Training, Performance, and Recovery N/A
Enrolling by invitation NCT04273776 - A Comparison of the Physiological and Behavioral Effects of Suvorexant and Zolpidem in Healthy Volunteers: A Randomized, Double-blind, Placebo Controlled Study Early Phase 1